Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR2 | Q16832 | 4/20 | 0.52 |
| ▸ | RAF1 | P04049 | 4/20 | 0.45 |
| ▸ | SRC | P12931 | 4/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.41 |
| ▸ | SYK | P43405 | 3/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | GSK3A | P49840 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15573105 | 0.92 | DDR2 (0.62) | DDR2RAF1SRCMAPK14SYK | |
| SCHEMBL16990734 | 0.91 | DDR2 (0.53) | DDR2RAF1TRPV1PPARGPPARD | |
| SCHEMBL16990646 | 0.90 | DDR2 (0.51) | DDR2RAF1SRCMAPK14SYK | |
| SCHEMBL15575289 | 0.89 | DDR2 (0.65) | DDR2RAF1PPARGPPARDPPARA | |
| SCHEMBL16990740 | 0.89 | DDR2 (0.55) | DDR2RAF1PPARGPPARDPPARA | |
| SCHEMBL16990681 | 0.88 | DDR2 (0.56) | DDR2RAF1PPARGPPARDPPARA | |
| SCHEMBL16990663 | 0.86 | DDR2 (0.54) | DDR2RAF1PPARGPPARDPPARA | |
| SCHEMBL16990580 | 0.86 | DDR2 (0.58) | DDR2RAF1PPARGPPARDPPARA | |
| SCHEMBL16990669 | 0.85 | DDR2 (0.50) | DDR2RAF1PPARGPPARDPPARA | |
| SCHEMBL17000079 | 0.85 | DDR2 (0.65) | DDR2RAF1SRCMAPK14SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | DDR2, DDR1, DDRGK1 | DDR2 1/4885RAF1 3072/4885SRC 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.